Epix Pharmaceuticals surges on positive cancer trial data

ESSA Pharma

26/10/2022 19:24

** Epix Pharmaceuticals Inc's shares  EPIX.O  rise 150.6% to
$4.3
    ** Co reports updated positive data on lead candidate 
EPI-7386 in treating patients with metastatic castrate-resistant
prostate cancer (mCRPC)  urn:newsml:reuters.com:*:nPn6dc8q0a
    ** The disease occurs when the cancer has spread to parts of
the body other than the prostate
    ** The early-to-mid-stage dose escalation study of EPI-7386
tested the drug in combination with enzalutamide on seven mCRPC
patients 
    ** EPI-7386 in combination with enzalutamide was safe and
well-tolerated at the doses tested, with clinically relevant
drug exposures observed in five of six patients - EPIX
    ** Co is also studying EPI-7386 in a separate early-stage
trial that was granted "fast track" designation by the U.S. FDA
for the treatment of adult male patients with mCRPC resistant to
standard-of-care treatment
    ** A fast track designation facilitates development and
expedites review of therapies with the potential to treat a
serious condition where there is an unmet medical need
    ** Including session's gain, stock down 70.1% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))